VK2735
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Viking Therapeutics · Phase 3 · Active, not recruiting · Enrollment 1100
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.